Novavax, Inc (NASDAQ: NVAX) on Tuesday, plunged -7.68% from the previous trading day, before settling in for the closing price of $7.03. Within the past 52 weeks, NVAX’s price has moved between $5.01 and $17.81.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 105.39%. The company achieved an average annual earnings per share of 298.25%. With a float of $147.60 million, this company’s outstanding shares have now reached $161.96 million.
The extent of productivity of a business whose workforce counts for 952 workers is very important to gauge. In terms of profitability, gross margin is 88.25%, operating margin of 32.78%, and the pretax margin is 38.93%.
Novavax, Inc (NVAX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Novavax, Inc is 8.87%, while institutional ownership is 56.77%. The most recent insider transaction that took place on May 19 ’25, was worth 75,883. Before that another transaction happened on Apr 14 ’25, when Company’s Former Director proposed sale 4,000 for $6.10, making the entire transaction worth $24,406.
Novavax, Inc (NVAX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 298.25% per share during the next fiscal year.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
Novavax, Inc (NVAX) is currently performing well based on its current performance indicators. A quick ratio of 2.03 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.65, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach 0.23 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
The latest stats from [Novavax, Inc, NVAX] show that its last 5-days average volume of 5.7 million was inferior to 6.82 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 9.11%. Additionally, its Average True Range was 0.48.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 30.90%, which indicates a significant increase from 2.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.43% in the past 14 days, which was lower than the 87.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.71, while its 200-day Moving Average is $8.74. Now, the first resistance to watch is $6.83. This is followed by the second major resistance level at $7.18. The third major resistance level sits at $7.37. If the price goes on to break the first support level at $6.30, it is likely to go to the next support level at $6.11. Assuming the price breaks the second support level, the third support level stands at $5.76.
Novavax, Inc (NASDAQ: NVAX) Key Stats
Market capitalization of the company is 1.05 billion based on 161,970K outstanding shares. Right now, sales total 682,160 K and income totals -187,500 K. The company made 666,660 K in profit during its latest quarter, and 518,650 K in sales during its previous quarter.
